Trial Profile
A study to investigate the influence of methylphenidate and atomoxetine in developing risk of depression in patients with Attention-deficit hyperactivity disorder verses controls that do not have ADHD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2016
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 20 Jul 2016 New trial record